Moving the Needle on Equity in Prostate Cancer

Menée aux Etats-Unis à partir de données portant sur 95 460 femmes transgenres (âge moyen : 52,5 ans), cette étude identifie les facteurs associés au risque de cancer de la prostate et au risque de récidive, et analyse la prévalence de la maladie (589 cas)

Résumé en anglais

As the number of individuals experiencing gender incongruence seeking health care increases worldwide, it is imperative to continue to improve cancer screening and diagnosis and treatment approaches to achieve more equitable outcomes for transgender and gender-diverse people. For transgender women, we must ensure equitable access to knowledgeable and competent high-quality health care, and prostate cancer screening and treatment is no exception.The article by Manfredi et al provides important information about prostate cancer in transgender women in the setting of data scarcity and adds to the growing literature that can guide future studies related to understanding the prevalence and risk factors for prostate cancer in transgender women as well as inform future clinical guidelines. Specifically, the data presented do not reveal a difference between prostate cancer screening in those receiving gender-affirming hormone treatment (GAHT) compared to those that are not, which is reassuring. However, these data do not provide insight into access to cancer screening or treatment, and data suggest that transgender women may overall be less likely to receive screening, in part due to clinician recommendation. In the absence of specific and actionable high-quality data for populations with unique risk factor profiles, such as transgender women, physicians must ensure that persons with prostates, irrespective of the type of gender-affirming care received, continue to receive the recommended appropriate standard screening.